Description

IBS symptom severity scores at baseline are compared between the synbiotic and placebo groups, establishing balanced starting conditions for the 8-week trial.

Figure 2

Chart

Source Paper

The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant …

Nutrients (2020)

PMID: 32635661

DOI: 10.3390/nu12071999

Cite This Figure

![Figure 2: IBS symptom severity scores at baseline are compared between the synbiotic and placebo groups, establishing balanced starting conditions for the 8-week trial.]()

> Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." *Nutrients*, 2020. PMID: [32635661](https://pubmed.ncbi.nlm.nih.gov/32635661/)

<figure>
  <img src="" alt="IBS symptom severity scores at baseline are compared between the synbiotic and placebo groups, establishing balanced starting conditions for the 8-week trial." />
  <figcaption>Figure 2. IBS symptom severity scores at baseline are compared between the synbiotic and placebo groups, establishing balanced starting conditions for the 8-week trial.<br>  Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32635661/">32635661</a></figcaption>
</figure>

Preuves associées

Bifidobacterium longum pour Irritable Bowel Syndrome (IBS)

Note B · 4 études

Galactooligosaccharides (GOS) pour Irritable Bowel Syndrome (IBS)

Note B · 3 études

Lactobacillus acidophilus pour Irritable Bowel Syndrome (IBS)

Note B · 3 études

Fructooligosaccharides (FOS) pour Irritable Bowel Syndrome (IBS)

Note D · 2 études